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ABSTRACT
Background
Integrative oncology uses both conventional and
complementary medicine to meet the needs of indi-
vidual patients and to focus on the whole person. The
core principles of integrative oncology include individu-
alization, holism, dynamism, synergism, and collabo-
ration, but the nature of the evidence to guide the
development of integrative oncology has been given
little attention.
Objectives
• To discuss the need for evidence to support the in-
tegration of complementary therapies for integra-
tive oncology care.
• To emphasize that the evidence base must be valid
and respect the underlying principles of individual
complementary therapies and integrative oncology
practice.
• To suggest ways to begin developing the evidence
base.
Review and Discussion
Although the evidence for safety and efficacy seems
paramount for supporting the integration of an individual
complementary therapy into mainstream cancer care,
the need for evidence to support the overall practice of
integrative oncology has to be considered as well.
We argue that developing an evidence base for in-
tegrative oncology requires a contextual and compre-
hensive research approach that assesses a range of
outcomes over a suitable period of time that the pa-
tient and the patient’s family, in addition to the health
care providers, deem important.
Conclusion
A whole-systems framework to the development of the
evidence base for integrative oncology can guide the
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development of evidence that respects the complex
nature of many complementary and integrative prac-
tices and their underlying principles of care delivery.
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1. INTRODUCTION
The field of integrative oncology has emerged as a re-
sponse both to cancer patients’ advocacy for holistic
care and to an increasing evidence base for the safety
and effectiveness of many complementary approaches,
commonly called complementary and alternative medi-
cine (CAM). Cancer patients desire care that not only
focuses on treating their disease, but also manages the
course of their illness experience, optimizing health and
enhancing well-being. Most cancer patients use comple-
mentary medicine alongside conventional medicine to
meet these needs 1–4. Complementary and alternative
medicine includes whole medical systems (Traditional
Chinese Medicine, among others), mind–body medicine
(for example, meditation), biologically-based practices
(natural health products, for instance), manipulative and
body-based therapies (for example, massage), and en-
ergy therapies (qi gong, among others) 5.
Integrative oncology uses both conventional medi-
cine and CAM to meet the needs of individual patients
and focuses on the whole person 6. At the core of inte-
grative oncology is the need for an evidence base to
support the use of conventional and complementary
treatments in a collaborative and synergistic manner.
The nature of the evidence to guide the development
of integrative oncology has, however, been given little
attention. In the present paper, we discuss the need for
evidence to support the integration of complementary
therapies for integrative oncology care; we emphasize
that the evidence base must be valid and must respect
the underlying principles of individual complementary
therapies and integrative oncology practice; and we
suggest ways to begin developing that evidence base.INTEGRATIVE ONCOLOGY PRINCIPLES
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2. WHAT IS INTEGRATIVE ONCOLOGY?
The goal of integrative oncology is to support cancer
patients and their families throughout the cancer jour-
ney by improving quality of life, ameliorating symp-
toms associated with conventional cancer care,
alleviating distress, and in some cases, augmenting the
effectiveness of conventional treatment 7,8. Mumber
defines integrative oncology as “a comprehensive, evi-
dence-based approach to cancer care that addresses
all participants at all levels of their being and experi-
ence. It represents the next step in the evolution of
cancer care in that it addresses the limitations of the
current system while retaining the system’s success-
ful features” 9.
Core principles of integrative oncology include in-
dividualization, holism, dynamism, synergism, and
collaboration. In integrative oncology, the focus of care
is on the whole person, and the aim is to promote the
innate ability of each person to heal. Integrative oncol-
ogy is individualized for each cancer patient over time,
as each patient presents with unique symptoms and
context, and as the goals of treatment change over time.
Integrative care is also about compassion and caring
for an individual in a holistic manner that gives voice
to the patient’s values and needs. Grounded in a truly
respectful partnership between patient and practitio-
ner, a therapeutic alliance is forged that honours the
patient’s informed choices. This collaborative approach
to cancer care assumes that conventional and com-
plementary practitioners—and patients—contribute
their knowledge, experience, and skills to the healing
encounter 8. In this context, a safe, knowledgeable,
and dynamic cancer management plan is developed
cooperatively, ensuring accurate monitoring and evalu-
ation 10. Further, and in contrast to the prevailing
pharmacologic model, the this cancer care approach
recognizes the potential for synergy when therapies are
integrated, with outcomes far exceeding the sum of the
outcomes of individual therapies.
Integrative oncology is usually defined as an evi-
dence-based discipline; however, we argue that the tra-
ditional (scientific) understanding of evidence needs
to be revisited and expanded.
3. THE NEED FOR EVIDENCE
Integrative oncology makes a deliberate, yet fluid, dis-
tinction between complementary therapies, which are
supported by evidence and used in combination with
conventional cancer care, and alternative therapies,
which are unproven and used as a replacement for con-
ventional cancer care 7,11. When a strong evidence base
is developed for some complementary therapies, they
can potentially become part of integrative cancer care.
For example, after a review of the available evidence,
the Society for Integrative Oncology supports the use
of acupuncture as a complementary therapy when can-
cer-related pain is poorly controlled 7.
The practice of integrative oncology therefore de-
pends mainly on complementary therapies meeting
standards of safety and, to a lesser extent, effective-
ness (because the latter may be assessed from differ-
ent perspectives in real-life situations). As a result, an
understanding of what constitutes appropriate evidence
is crucial to the foundation and future development of
the field.
Despite agreement on the need for evidence to
support the integration of complementary therapies into
conventional cancer care 7,9,11, the discussion regard-
ing the type of evidence required and its purpose is
entirely based on evidence from specific CAM treat-
ments. We argue that this line of thinking misses an
important point. To begin the discussion, a distinction
must first be made between evidence for complemen-
tary therapies and evidence for integrative oncology
practice. The first issue concerns evidence that sup-
ports the safety and effectiveness of individual comple-
mentary therapies, thus determining their suitability for
integration into mainstream care. The second—and
often forgotten—aspect concerns evidence that sup-
ports the synergistic integration of complementary and
conventional practices in a collaborative and support-
ive manner within cancer care.
3.1 Nature of the Evidence Required for
Complementary Therapies
According to Stark, Hess, and Shaw 12, different lev-
els of evidence are required for the safety and effec-
tiveness of individual complementary therapies
depending on the goals of treatment. These levels of
evidence depend on study design and sample size, and
they range from well-designed randomized controlled
trials [RCTs (level 1)] to preclinical in vitro and in vivo
studies and traditional medicines (level 4). Level 1
evidence is required for the use of complementary
therapies with anti-neoplastic goals, but lower levels
of evidence, such as nonrandomized trials or observa-
tional studies, are acceptable for less-invasive proce-
dures and preventive or supportive goals. However, this
hierarchy does not capture the multidisciplinary, syn-
ergistic approach that characterizes complementary
therapies and integrative oncology alike in comparison
with conventional care 10. Further, while addressing
the need for evidence to support the individual integra-
tion of a complementary therapy into mainstream care,
the need for evidence to support the overall practice of
integrative oncology is often ignored.
A need arises to revisit traditional notions of evi-
dence as they apply to complementary therapies.
Traditional research methods are challenged in the at-
tempt to evaluate complementary therapies, because
these methods cannot account for the fundamental is-
sues of individualization, synergism, and holism 8,9,13.
These problems are compounded for the evaluation
of integrative oncology, which involves the synergis-
tic use of treatments from various healing paradigmsLEIS et al.
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and a range of physiologic, emotional, social, and
spiritual outcomes.
3.2 Nature of the Evidence Required for
Integration
Further to answering whether a complementary therapy
works and is safe, questions regarding the appropriate-
ness of integration must be examined. To this end, it is
critical to document the ways in which complemen-
tary therapies and conventional care are being inte-
grated and the outcomes that are important and relevant.
Integration can occur at many levels: individual,
clinical, institutional, regulatory, or policy 14. Integra-
tion can also occur in many ways. For example, numer-
ous patients are known to be integrating complementary
therapies into their conventional care, but research is
only starting to uncover how those patients make deci-
sions regarding therapy selection, who is involved in
the decision-making process, why the patients are in-
tegrating these therapies, and which outcomes are seen
as relevant 15. Alternatively, health care providers may
be the ones suggesting integration for their patients.
The process of evaluation and decision-making is likely
different in the two scenarios, in part because the in-
tent may differ. For the health care professional, for
example, the utmost concern is patient safety; but for
patients, a decision to use CAM may be driven by an
attempt to minimize potential side effects and to feel
empowered 16.
“Integrating” must also be distinguished from “com-
bining.” “Combining” is more akin to adding various
therapies to a treatment plan without considering the
overall picture. “Integrating” involves synergistically
applying a range of treatments to address holistic treat-
ment goals as they change over time and in accordance
with patient needs and values. Currently, although the
goals and philosophy underlying integrative oncology are
well developed, practical knowledge is not available
concerning the extent to which and the manner in which
diverse therapies are being integrated or combined.
Finally, integrative care seems to represent un-
tapped opportunities (which so far remain understud-
ied) for meeting the needs of cancer patients across
the cancer trajectory.
4. VALIDITY AS CRITERION FOR EVIDENCE
As development of an evidence base begins both for
individual complementary therapies and for integra-
tive oncology, assurance is needed that the evidence
base is valid—“validity” referring to the extent that
appropriate research methods were used to support a
conclusion regarding the efficacy or effectiveness of
a therapy.
“Validity” commonly includes internal validity and
external validity. Model validity is separate from both
of those, but is just as important. Model validity is of-
ten overlooked because of the biomedical focus of most
health care research. It refers to the extent to which
the research methods used have addressed the unique
theory and therapeutic context of the intervention be-
ing assessed 17.
Traditional clinical research methods have been
developed to assess biomedical interventions, and thus
model validity can typically be assumed. For research
results to be valid in the case of integrative oncology,
the research methods used must address the underly-
ing principles of integrative oncology, such as its indi-
vidualized, synergistic, holistic, and collaborative
nature. The same is true for research regarding indi-
vidual complementary therapies that are often based
on assumptions contrary to biomedicine, such as the
network of channels and blood vessels connected by qi
(an essential fast-flowing substance full of vigour) in
an approach using Traditional Chinese Medicine.
4.1 Limitations of the RCT Design for
Complementary Therapies and Integrative
Oncology
The double-blind RCT is often upheld as the “gold stan-
dard” in clinical research, because of its strong inter-
nal validity arising from the ability to control for
expected and unexpected bias, confounding factors, and
error. However, it is impossible to achieve model va-
lidity while applying the blinded RCT design to the prac-
tice of integrative oncology and many complementary
therapies 13.
Sagar 8 highlights several of the key challenges in
applying the RCT design to the study of select comple-
mentary therapies. Examples include difficulties in
determining appropriate placebos or sham treatments,
the impossibility of double-blinding when the practi-
tioner is part of the intervention, and problems respect-
ing the individualized approach of many complementary
practices. Acupuncture provides a good example, be-
cause the choice of an appropriate sham treatment for
acupuncture has been an ongoing challenge 18, not un-
like that in determining an appropriate sham treatment
for surgery in the realm of conventional care. Further,
blinding patients and providers is difficult, because both
are quite aware of whether needling has taken place,
although single-blinding may be possible if simulated
needling is used as a sham treatment. In practice, dif-
ferent needling protocols are developed for specific
patients, depending on their unique symptoms and ho-
listic context, and thus standardization of an acupunc-
ture protocol for a RCT is problematic if model validity
is to be upheld.
The same argument can easily be extended to in-
tegrative oncology practice, in which therapies from
diverse philosophical backgrounds are combined, thus
making model validity even more difficult to attain. In
addition to the problems of defining a placebo, blind-
ing, and standardization, the RCT is not designed to
measure the effect that each patient’s unique physical,
social, and cultural context and corresponding reasonsINTEGRATIVE ONCOLOGY PRINCIPLES
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for integration may have on treatment outcomes. Fur-
ther, the RCT cannot assess the synergism that results
from the integration of various therapies, coupled with
the healing context and the clinical skills and expertise
of the integrative team.
4.2 Building Evidence for Integrative Oncology
Developing an evidence base for integrative oncology
requires a contextual and comprehensive research ap-
proach that assesses a range of outcomes over a suit-
able period of time that the patient, the patient’s family,
and health care providers deem important. We next
highlight some approaches that begin to meet the re-
quirements of internal, external, and model validity.
Readers should consult the papers referenced in this
section for detailed descriptions of these approaches.
4.2.1 Variations of the RCT Design
Although the RCT in its classical form cannot meet the
requirements for model validity when applied to
complementary therapies or integrative oncology, some
variations have been suggested that address many of
the shortcomings. For example, pragmatic RCTs do not
require standardization of the intervention and thus al-
low for the individualized nature of the treatments to
be assessed. Preference RCTs account for the effect
that beliefs and preferences of patients for certain treat-
ment types will have on treatment outcomes. In a pref-
erence RCT, patients with treatment preferences
receive their preferred treatment; patients who do not
have a preference are randomized as usual.
4.2.2 The Power of Mixed Methods
Although quantitative research approaches have been
well established in evaluating treatment interventions,
the importance of qualitative research cannot be over-
looked or dismissed as development begins of the evi-
dence base for complementary therapies and integrative
oncology. Qualitative research has amazing potential
to explore, in depth, from a variety of perspectives (pa-
tients, oncology team, cancer care system), how inte-
grative cancer treatment and care are experienced.
Including qualitative inquiry in the evaluation of inter-
ventions should be an integral part of evidence-based
medicine 19.
Qualitative research aims to understand the nature
of phenomena; it will prove crucial as exploration of
the potential of integrative oncology for cancer care
moves forward. For example, qualitative research is
ideally suited to answer the question of what integra-
tive oncology is, how it is being practiced, how it can
best be practiced, and the benefits that are possible.
Such exploratory work can help to elucidate the key
components in integrative care and their synergistic
relationships from the viewpoint of patients and of prac-
titioners.
Because qualitative research can fill an important
niche in this field, it should, when possible, be nested
within clinical trials or other quantitative designs 20,21
as a form of mixed-methods research. Such a design
represents a further modification of the RCT method
that addresses the requirements of internal, external,
and model validity. This approach can help to elicit
whether, why, and how patients benefit from a com-
plex intervention and can explore relevant outcomes
from a variety of perspectives.
4.2.3 Whole-Systems Research
Whichever research methods are ultimately adopted
to study complementary therapies and integrative on-
cology, investigators must systematically capture the
complexity inherent in these approaches to healing. A
“whole-systems” research framework is helpful to
conceptualize the important issues that need attention
and to design step-wise programs of research that will
answer the multifaceted questions.
The notion of whole-systems research has recently
been given attention in the literature, both with regard
to complementary therapies 13,22 and integrative on-
cology 23,24. In a general sense, the goal of whole-
systems research “is to appropriately combine research
designs and methods in a coherent research program,
so that all aspects of an internally consistent approach
to treatment, or a whole system, can be assessed. It
acknowledges an individualized, patient centered and
participatory approach to diagnosis and treatment and
a process of healing that collaboratively combines pa-
tient and practitioner knowledge and skills, thus en-
hancing healing” 23.
The relevance of a whole-systems framework to
the development of the evidence base for integrative
oncology should be apparent. It can guide the develop-
ment of evidence that respects the complex nature of
many complementary and integrative practices and their
underlying principles of care delivery 25. A program of
research guided by a whole-systems research frame-
work would include RCTs, variations of RCTs, obser-
vational trials, and qualitative research, ideally mixing
methods as appropriate, depending on the specific fo-
cus. A program of whole-systems research would thus
produce research that collectively has strong validity.
5. CONCLUSIONS
As cancer patients increasingly turn to CAM as a way
to complement their cancer care, it is crucial that health
care professionals become informed about the evidence
base behind this group of practices 26 and, further, that
they remain critical of the need for valid research. The
assessment of validity for complementary therapies and
integrative oncology alike should encompass internal,
external, and model validity. Because it seems unlikely
that any one study design can achieve optimal levels
of each type of validity, health professionals and re-
searchers need to be open to emerging models of evi-
dence that are not necessarily aligned to traditional ideas
of evidence in biomedicine. Programs of research haveLEIS et al.
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to include a variety of evidence types and treat all of
them as legitimate. A whole-systems research frame-
work is helpful to guide the development of these re-
search programs.
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